Since launching Spravato (intranasal esketamine) treatment at LouCouPsych, there has been genuine excitement and buzz, with great interest in the outcomes. As of this writing, we have 3 patients who have agreed to give feedback and allow publication of their responses to some questions. Dr. Mirza and staff have noticed a tremendous return on investment, with mood and function significantly improving, often quite rapidly. Below is a live and continuously updating graph showing individual responses to treatment over time in weeks against their PHQ-9 scores, a way to objectively quantify depression.
As can be seen, individuals were scoring in the "Moderately-severe" to "Severely" depressed range were down to "Minimal-to-none" within weeks. That is a game changer.
Regarding the experience as a whole, here is a bit more detailed report.
To start your journey with Spravato (intranasal esketamine) for treatment resistant depression, or to learn more, please contact us today!
